Interpace Diagnostics Group (NASDAQ:IDXG) received a $2.00 target price from analysts at Maxim Group in a research note issued on Monday, TipRanks reports. The firm currently has a “buy” rating on the business services provider’s stock. Maxim Group’s target price points to a potential upside of 153.16% from the stock’s current price.
Other equities analysts also recently issued reports about the stock. HC Wainwright set a $2.00 target price on shares of Interpace Diagnostics Group and gave the company a “buy” rating in a report on Friday, October 18th. Oppenheimer assumed coverage on shares of Interpace Diagnostics Group in a report on Thursday, September 26th. They set an “outperform” rating and a $3.00 target price for the company. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Interpace Diagnostics Group currently has an average rating of “Buy” and an average price target of $2.33.
Shares of IDXG traded up $0.01 during trading hours on Monday, reaching $0.79. The company had a trading volume of 45,593 shares, compared to its average volume of 244,097. The firm has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $0.76. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $30.42 million, a price-to-earnings ratio of -1.84 and a beta of 2.29. Interpace Diagnostics Group has a 12-month low of $0.67 and a 12-month high of $1.55.
A number of large investors have recently bought and sold shares of IDXG. Cambridge Investment Research Advisors Inc. increased its holdings in Interpace Diagnostics Group by 98.0% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock valued at $32,000 after acquiring an additional 22,150 shares in the last quarter. River & Mercantile Asset Management LLP purchased a new position in Interpace Diagnostics Group during the 2nd quarter valued at about $468,000. Stonepine Capital Management LLC increased its holdings in Interpace Diagnostics Group by 22.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock valued at $1,271,000 after acquiring an additional 319,154 shares in the last quarter. Finally, Perkins Capital Management Inc. increased its holdings in Interpace Diagnostics Group by 22.5% during the 3rd quarter. Perkins Capital Management Inc. now owns 2,360,385 shares of the business services provider’s stock valued at $1,876,000 after acquiring an additional 433,135 shares in the last quarter. Hedge funds and other institutional investors own 19.03% of the company’s stock.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Further Reading: Why do earnings reports matter?
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.